Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

Mary D. Ruppe,Xiaoping Zhang,Erik A. Imel,Thomas Weber,Mark A. Klausner,Takahiro Ito,Maria Vergeire,Jeffrey Humphrey,Francis H. Glorieux,Anthony A. Portale,Karl L. Insogna,Munro Peacock,Thomas O. Carpenter

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia

2016

Mary D. Ruppe
Xiaoping Zhang
Erik A. Imel
Thomas Weber
Mark A. Klausner
Takahiro Ito
Maria Vergeire
Jeffrey Humphrey
Francis H. Glorieux
Anthony A. Portale
Karl L. Insogna
Munro Peacock
Thomas O. Carpenter

X-linked hypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated levels of fibroblast growth factor 23 (FGF23).

Keywords:

Antibody
X-linked hypophosphatemia
Immunology
Monoclonal
Medicine
Quality of life
health related quality of life
Endocrinology
Diabetes mellitus
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations